Celyad SA (1C0) Stock Price & Analysis

1 Followers

1C0 Stock Chart & Stats

€0.16-€0.01(-5.88%)

At close: Nov 02 5:30 PM GMT+1

Day’s Range: EUR 0.16 - EUR 0.16
52-Week Range: EUR 0.13 - EUR 0.46
Previous Close: EUR 0.17
Volume: N/A
Average Volume (3M): 0
Market Cap: EUR 9.45M
Enterprise Value: EUR 10.65M
Total Cash (Recent Filing): EUR 4.20M
Total Debt (Recent Filing): EUR 17.54M
Price to Earnings (P/E): 2.4
Beta: 0.02
Next Earnings: Mar 25, 2027 (Est.)
EPS Estimate: N/A
Next Dividend Ex-Date: N/A
Dividend Yield: N/A

Celyad SA News

Celyad Oncology Narrows Loss as Cost Cuts and Asset Sales Extend Cash Runway

Celyad SA ( ($CLYYF) ) has shared an announcement. Celyad Oncology reported a sharply reduced net loss for the first half of 2026, as aggressive cost-cutting and asset divestments lowered

1M agoCLYYF 1C0

Celyad Oncology Discloses Drop in Tolefi Stake Below 10% Threshold

An announcement from Celyad SA ( ($CLYYF) ) is now available. Celyad Oncology has disclosed that long‑time shareholder Tolefi SA and related persons have passively reduced their combined stake below

3M agoCLYYF 1C0

Celyad Oncology Updates Capital and Voting Structure After Fortress Share Issue

An update from Celyad SA ( ($CLYYF) ) is now available. Celyad Oncology has strengthened its capital base following the issuance of 2,500,000 new shares to an affiliate of Fortress

3M agoCLYYF 1C0

Celyad Oncology Reports First Half 2025 Results

Celyad Sa otc ( ($CLYYF) ) has released its Q2 earnings. Here is a breakdown of the information Celyad Sa otc presented to its investors. Celyad Oncology is a biotechnology

1y agoCLYYF 1C0

Celyad Oncology Reports 2024 Financial Results and Advances in CAR T-Cell Therapies

Celyad Sa otc ( ($CLYYF) ) has released its Q4 earnings. Here is a breakdown of the information Celyad Sa otc presented to its investors. Celyad Oncology is a biotechnology

1y agoCLYYF 1C0

Celyad receives Nasdaq initial notification on ADS bid price

Celyad Oncology received a letter on April 19th, 2023 from The Nasdaq Stock Market informing the company that the minimum closing bid price per share of its American Depositary Shares

3y agoCYAD CLYYF

Celyad receives noncompliance letter from Nasdaq

Celyad received a letter on March 31 from Nasdaq informing the company that it failed to maintain the continued listing requirement under Nasdaq Listing Rule 5450 for the Nasdaq Global

3y agoCYAD CLYYF

Celyad discloses Nasdaq listing notice

Celyad Oncology received a letter on March 31, 2023 from The Nasdaq Stock Market informing the Company that it failed to maintain the continued listing requirement under Nasdaq Listing Rule

3y agoCYAD CLYYF

Celyad names Georges Rawadi as new CEO

Celyad Oncology is pleased to announce Georges Rawadi as its new CEO, effective as of March 23, with starting date April 17. Michel Lussier will continue to serve as Interim

3y agoCYAD CLYYF

Celyad to recognize non-cash impairment of EUR 35.1M for FY22

Celyad announced a non-cash impairment of its goodwill and intangible oncology assets.This impairment comes as a result of the company’s strategic shift in focus away from clinical development and the

3y agoCYAD CLYYF

Celyad to entirely focus on new business strategy

In a shareholder letter, Celyad interim CEO Michel Lussier and Chair Hilde Windels said in part, "This stream of events in the first months of 2022 led to the decision

3y agoCYAD CLYYF

Biotech Alert: Searches spiking for these stocks today

Stay ahead of biotech stocks seeing a surge in interest from retail and financial professional investors with this exclusive recap from The Fly These names in the biotech sector are

3y agoAUTL AVRO

Celyad poblishes data from haematological arm of THINK study

Celyad announced the publication of the data from the haematological arm of the THINK study which evaluated CYAD-01 in relapsed or refractory acute myeloid leukaemia, or AML, and myelodysplastic syndromes,

3y agoCYAD CLYYF

Lava Therapeutics appoints Charles Morris as CMO

LAVA Therapeutics (LVTX) announced that Dr. Charles Morris has joined LAVA as chief medical officer effective February 6, 2023. Dr. Morris will replace Benjamin Winograd, MD, PhD. Most recently, Morris

3y agoCYAD LVTX

1C0 FAQ

What was Celyad SA’s price range in the past 12 months?

Celyad SA lowest stock price was €0.13 and its highest was €0.46 in the past 12 months.

What is Celyad SA’s market cap?

Celyad SA’s market cap is €9.45M.

When is Celyad SA’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Celyad SA’s earnings last quarter?

Celyad SA released its earnings results on Sep 23, 2026. The company reported -€0.027 earnings per share for the quarter.

Is Celyad SA overvalued?

Not enough analysts have published a price target to calculate whether the price is overvalued.

Does Celyad SA pay dividends?

Celyad SA does not currently pay dividends.

What is Celyad SA’s EPS estimate?

Celyad SA’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Celyad SA have?

Celyad SA has 47,261,906 shares outstanding.

What happened to Celyad SA’s price movement after its last earnings report?

Celyad SA reported an EPS of -€0.027 in its last earnings report. Following the earnings report the stock price went up 9.424%.

Which hedge fund is a major shareholder of Celyad SA?

Currently, no hedge funds are holding shares in DE:1C0

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Celyad SA

Celyad Oncology S.A. is a clinical-stage biopharmaceutical firm dedicated to pioneering and advancing chimeric antigen receptor T (CAR-T) cell therapies specifically for oncology. Its most advanced therapeutic programs include several candidates undergoing clinical trials. CYAD-101 is an allogeneic CAR-T treatment currently in a Phase 1b study targeting metastatic colorectal cancer. Another allogeneic candidate, CYAD-211, utilizes short hairpin RNA (shRNA) technology and is being evaluated in a Phase 1 trial for patients with relapsed or refractory multiple myeloma. Furthermore, CYAD-02, an autologous CAR-T therapy, is progressing through a Phase 1 study to address relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. In its preclinical pipeline, the company is developing CYAD-203. This is a non-gene-edited allogeneic CAR-T candidate designed to co-express interleukin-18 (IL-18) cytokine with natural killer group 2D ligands (NKG2D), intended for the treatment of various solid tumors. Celyad Oncology holds a licensing agreement with Novartis International AG, granting rights to U.S. patents concerning allogeneic CAR-T cells. Additionally, it has established research and development collaborations and licensing agreements with Horizon Discovery Group plc, leveraging their shRNA technology to create an alternative non-gene-edited allogeneic platform. Established in 2004, the company was initially known as Celyad SA before rebranding to Celyad Oncology SA in June 2020. Its headquarters are situated in Mont-Saint-Guibert, Belgium.

Celyad SA (1C0) Earnings & Revenues

Historic Earnings Reports

Technical Analysis

Overall Consensus

Indicator	Bullish	Neutral	Bearish
Overall Consensus	5	4	13
Technical Analysis	4	4	2
Moving Averages	1	0	11

Technical Analysis >

Popular Stocks

Popular Stocks
Company	Price & Change	Follow
NVDANvidia
AAPLApple
MSFTMicrosoft

1C0 Stock Chart & Stats

Celyad SA News

Celyad Oncology Narrows Loss as Cost Cuts and Asset Sales Extend Cash Runway

Celyad Oncology Discloses Drop in Tolefi Stake Below 10% Threshold

Celyad Oncology Updates Capital and Voting Structure After Fortress Share Issue

Celyad Oncology Reports First Half 2025 Results

Celyad Oncology Reports 2024 Financial Results and Advances in CAR T-Cell Therapies

Celyad receives Nasdaq initial notification on ADS bid price

Celyad receives noncompliance letter from Nasdaq

Celyad discloses Nasdaq listing notice

Celyad names Georges Rawadi as new CEO

Celyad to recognize non-cash impairment of EUR 35.1M for FY22

Celyad to entirely focus on new business strategy

Biotech Alert: Searches spiking for these stocks today

Celyad poblishes data from haematological arm of THINK study

Lava Therapeutics appoints Charles Morris as CMO

1C0 FAQ

Company Description

Celyad SA

Celyad SA (1C0) Earnings & Revenues

Technical Analysis

Overall Consensus

Popular Stocks

Become an Expert with TipRanks Premium